Radius Health, Inc. (NASDAQ:RDUS) has been assigned a consensus recommendation of “Hold” from the eleven ratings firms that are presently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $56.40.

A number of equities analysts recently weighed in on the stock. ValuEngine raised shares of Radius Health from a “strong sell” rating to a “sell” rating in a research note on Friday. Cantor Fitzgerald reissued a “buy” rating and set a $58.00 target price on shares of Radius Health in a research note on Friday, November 3rd. Jefferies Group lowered their target price on shares of Radius Health from $38.00 to $31.00 and set a “hold” rating for the company in a research note on Friday, November 3rd. Goldman Sachs Group reissued a “neutral” rating and set a $45.00 target price on shares of Radius Health in a research note on Friday, October 6th. Finally, Zacks Investment Research downgraded shares of Radius Health from a “hold” rating to a “sell” rating in a research note on Wednesday, October 4th.

Shares of Radius Health (RDUS) traded down $0.44 during midday trading on Thursday, reaching $27.87. 702,158 shares of the company were exchanged, compared to its average volume of 1,059,109. Radius Health has a fifty-two week low of $24.66 and a fifty-two week high of $55.30. The company has a quick ratio of 12.79, a current ratio of 12.87 and a debt-to-equity ratio of 0.53.

Radius Health (NASDAQ:RDUS) last announced its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.03). The company had revenue of $13.50 million for the quarter, compared to analyst estimates of $6.90 million. During the same period in the previous year, the company earned ($1.07) earnings per share. research analysts predict that Radius Health will post -5.4 EPS for the current fiscal year.

In other Radius Health news, CFO Jose Carmona acquired 3,000 shares of Radius Health stock in a transaction dated Thursday, September 14th. The stock was purchased at an average cost of $32.83 per share, for a total transaction of $98,490.00. Following the completion of the acquisition, the chief financial officer now directly owns 3,000 shares of the company’s stock, valued at $98,490. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Jesper Hoiland acquired 6,100 shares of Radius Health stock in a transaction dated Friday, September 15th. The shares were acquired at an average price of $32.72 per share, with a total value of $199,592.00. Following the completion of the acquisition, the insider now directly owns 6,100 shares of the company’s stock, valued at $199,592. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 417,678 shares of company stock valued at $13,583,998. Insiders own 15.00% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Belpointe Asset Management LLC acquired a new position in shares of Radius Health during the third quarter valued at about $474,000. Cubist Systematic Strategies LLC acquired a new position in shares of Radius Health during the third quarter valued at about $110,000. Point72 Asset Management L.P. acquired a new position in shares of Radius Health during the third quarter valued at about $17,236,000. Orbimed Advisors LLC grew its holdings in shares of Radius Health by 59.5% during the third quarter. Orbimed Advisors LLC now owns 1,122,800 shares of the biopharmaceutical company’s stock valued at $43,284,000 after buying an additional 418,700 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. grew its holdings in shares of Radius Health by 28.4% during the third quarter. Schwab Charles Investment Management Inc. now owns 180,901 shares of the biopharmaceutical company’s stock valued at $6,974,000 after buying an additional 40,006 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: “Brokerages Set Radius Health, Inc. (RDUS) Target Price at $56.40” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/12/03/brokerages-set-radius-health-inc-rdus-target-price-at-56-40.html.

About Radius Health

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Receive News & Stock Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related stocks with our FREE daily email newsletter.